Peripheral T-cell tolerance in hosts with acute myeloid leukemia

OncoImmunology

Volumn 2, Issue 8, 2013, Pages

  Chen, Xiufen ^a   Kline, Douglas E ^a   Kline, Justin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

AML; Anergy; APC; Deletion; Peripheral tolerance

Indexed keywords

GAG PROTEIN; LYMPHOCYTE ANTIGEN; SIY ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL MATURATION; CELLULAR IMMUNITY; CLONAL ANERGY; HOST RESISTANCE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; NONHUMAN; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; TUMOR IMMUNITY;

EID: 84885783195     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25445     Document Type: Article

References (10)

1. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006; 213:131-45; PMID:16972901; http://dx.doi. org/10.1111/j.1600-065X.2006.00442.x
2. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002; 71:907-20; PMID:12050175
3. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010; 59:1593-600; PMID:20414655; http://dx.doi.org/10.1007/s00262- 010-0855-8
4. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009; 114:1545- 52; PMID:19417208; http://dx.doi.org/10.1182/ blood-2009-03-206672
5. Zhang L, Chen X, Liu X, Kline DE, Teague RM, Gajewski TF, et al. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest 2013; 123:1999-2010; PMID:23619361; http://dx.doi. org/10.1172/JCI63980
6. Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ. Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med 1995; 182:821- 8; PMID:7650488; http://dx.doi.org/10.1084/ jem.182.3.821
7. Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999; 5:774-9; PMID:10395322; http://dx.doi.org/10.1038/10495
8. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998; 95:1178-83; PMID:9448305; http://dx.doi. org/10.1073/pnas.95.3.1178
9. Teague RM, Sather BD, Sacks JA, Huang MZ, Dossett ML, Morimoto J, et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 2006; 12:335-41; PMID:16474399; http://dx.doi.org/10.1038/nm1359
10. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J Exp Med 2011; 208:2005-16; PMID:21930765; http://dx.doi. org/10.1084/jem.20101159